NFKB1 and diffuse large B-cell lymphoma: Our analysis motivates further studies focusing on therapeutic strategies targeting NF-κB, JAK-STAT, NOTCH signaling, and the PD-1/ PD-L1 axis in patients with EBV + DLBCL.